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Hormone therapy continues to be a favourable option in the management of menopausal 
symptomatology, but the associated risk-benefit ratios with respect to neurodegenerative diseases 
remain controversial. The study aim was to determine the relation between menopausal hormone
therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. A literature search 
was performed in PubMed/Medline, Cochrane collaboration, and Scopus databases from onset of the 
database to September 2019. Random-effects model was used to estimate pooled odd ratio (OR) and 95% 
confidence intervals (CI). Subgroup analysis was performed based on the type and formulation of 
hormone. In addition, the time-response effect of this relationship was also assessed based on duration of 
hormone therapy. Associations between hormone therapy and Alzheimer's disease, dementia, and 
Parkinson's disease in menopausal women were reported in 28 studies. Pooled results with random effect 
model showed a significant association between hormone therapy and Alzheimer's disease (OR 1.08, 95% 
CI 1.03 -1.14, I2: 69%). This relationship was more pronounced in patients receiving the combined estrogen-
progestogen formulation. Moreover, a significant non-linear time-response association between hormone 
therapy and Alzheimer's disease was also identified (Coef1 = 0.0477, p1<0.001; Coef2 = -0.0932, p2<0.001). 
Similarly, pooled analysis revealed a significant association between hormone therapy and all-cause 
dementia (OR 1.16, 95% CI 1.02 -1.31, I2: 19%). Interestingly, no comparable relationship was uncovered 
between hormone therapy as a whole and Parkinson's disease (OR 1.14, 95% CI 0.95-1.38, I2: 65%); however, 
sub-group analysis revealed a significant relationship between the disease and progestog n (OR 3.41, 95% 
CI 1.23 - 9.46) or combined estrogen-progestogen formulation use (OR 1.49, 95% CI 1.34 - 1.65). Indeed, this 
association was also found to be driven by duration of exposure (Coef1 =0.0626, p1=0.04). This study reveals 
a significant direct relationship between the use of certain hormonal therapies and Alzheimer's disease, all-
cause dementia, and Parkinson's disease in menopausal women. However, the association appears to shift 
in direct after five years in the context of A zheimer’s disease, adding further weight to the critical window 
or timing hypothesis of neurodegeneration and neuroprotection. 
 






1. Introducti n 
 
Alzheimer’s disease and Parkinson’s disease remain the most prevalent neurodegenerative disorders 
worldwide (1). While the two diseases are entirely distinct in their pathogenesis, they occasionally converge 
upon the coexistence of dementia. Dementia is a clinical syndrome of major cognitive impairment with a 
variety of underlying etiologies, the most common being Alzheimer’s disease, with several other vascular 
causes following in prevalence and Parkinsonian-related dementia representing a relatively uncommon 
but further debilitating presentation of the syndrome. While 
 
 
there exist several competing or complementary hypotheses on the development of Alzheimer’s and 
Parkinson’s disease, the exact underlying etiologies remain uncertain and no single lifestyle or genetic 
factor can be implicated at present. Interestingly, however, Alzheimer’s and dementia are notably 
imbalanced between sexes, with significantly higher prevalence and indeed incidence rates in females 
 
(2). Although female longevity goes some of the way in explaining this prevalence disparity, 
researchers have now begun to query the involvement of sex-dependent hormones in the 
pathogenesis of these diseases. 
 
The vasomotor symptomatology which so often accompanies the menopause can be debilitating and 
life-limiting for certain women. In line with this, the use of hormone therapy (HT) to negate such 
symptoms has become commonplace due to the ease of administration and efficacy f such treatments 
(3, 4). These therapies involve the application of estrogen, or its bioequivalent f rm, either alone or in 
combination with progesterone or its synthetic forms (3, 4). The esults f the Women’s Health Initiative 
indicate that while HT is an effective treatment for meno ausal symptom reduction, there are various 
risks associated with their use which are not entirely negligible (5). For example, while it was 
suggested that HT may decrease risk of hip fracture and colorectal cancer, there also appears to be an 
increased risk of breast cancer and stroke (5). How v r, the impact of hormone replacement therapy on 
risk of cognitive impairment and neurodegene ative disorders remains highly contentious (6). 
 
Although a number of studies have been conducted to examine the relationship between HT and the 
aforementioned neurodegener tive disorders, the results remain inconsistent and fail to bring 
consensus to the field. In order to ddress these inconsistencies in the literature and to further explore 
factors which potentially may drive these discrepancies, we performed a time-response meta-analysis 
evaluating the influence of me opausal HT on Alzheimer’s disease, Parkinson’s disease and all-cause 
dementia development. 
 
2. Materials and methods 
 
2.1. Search Strategy 
 
The MOOSE were followed to conduct this meta-analysis (7). A comprehensive systematic literature 
searches of related studies was conducted in PubMed/MEDLINE, Scopus, and Cochrane databases 
from inception to September 2019. Supplementary Table 1 outlines the specific search strategies 
applied for each database. The references from relevant papers were examined to identify any 
 
 
additional studies and an email alert service was activated in order to avoid missing any new articles 
published after the completion of our systematic search. 
 
2.2. Inclusion criteria 
 
Studies which met the following inclusion criteria were considered for this review: 1) authors 
investigated the association between menopausal HT and Alzheimer's disease, dementia, or 
Parkinson's disease; 2) used a case-control, controlled trial, or cohort design; 3) reported appropriate 
estimates for outcomes or provided the data required for derivation of these estimates. All review 
papers, editorials, letter to editor, non-human studies, in vitro research, case reports, ecological studies, 
or letters without sufficient data were excluded from this study. 
 
2.3. Data extraction and quality assessment 
 
Screening of studies was conducted using a predesigned screening form and two independent authors 
screened studies according to the inclusion criteria in a two step rocess: title and/or abstract 
 
screening, followed by full text screening. Any discrepancies which arose during screening were 
resolved by senior author. Subsequently, two authors ind p nd ntly extracted the following relevant 
data from the included studies: first author, year of publication, study location, type of used hormone, 
design of study, number of participants, age, identified confounding factors, and summary estimates 
with 95% CIs of Alzheimer's disease, dementia, and arkinson's disease. The fully adjusted models 
were used for all analysis in this study. The Newcastle-Ottawa Quality Assessment Scale (NOS) used 
to quality assessment of the included studies (8) . 
 
2.4. Statistical analysis 
 
All statistical analyses in this meta-analysis were performed using STATA 14.0 statistical software (Stata 
Corporation, College Station, Texas, USA). The random-effects model (DerSimonian and Laird) was 
applied in rder to combine outcomes results (9). The mean (or median) in each category of HT was 
considered as the reference category, when authors did not provide this data. Heterogeneity among results 
of included studies was estimated with Cochran’s Q test and I2 statistic. Meta-regressions based on baseline 
age of participants and subgroup analysis of HT based on design of primary study, as well as the type of 
hormone used, were conducted to identify potential sources of heterogeneity. In addition, sensitivity 
analysis was run to examin the effect of each study on the pooled result. The trim and fill approach was 
used to adjust for publication bias among included 
 
 
studies. Potential curvilinear associations between duration of HT and incidence of Alzheimer's 
disease, dementia, and Parkinson's disease were evaluated with three knots in 10%, 50%, and 90% of 
the distribution by restricted cubic splines method(10). Finally, publication bias was evaluated using 




3.1. Literature search 
 
Figure 1 presents a flow chat of the systematic search and inclusion of studies in this meta-analysis. 
through this comprehensive systematic search of PubMed/Medline, Sc pus, and Cochrane 
collaboration databases, 731 papers were initially identified, of which 216 were f und to be duplicates. 
From remaining studies, 480 papers failed to meet the inclusion crite ia and were excluded during title 
and/or abstracts screening, while an additional seven records we e excluded following full text 
evaluation. Ultimately, 28 papers were included in this meta-analysis (11-38). 
 
3.2. Study characteristics and quality assessment 
 
Tables 1 displays the relevant information of all includ d studi s. The studies, which were published 
between 1994-2019, included 14 case-control studies (11, 13, 15, 22, 26-28, 30-34, 37, 38), two RCTs (14, 
19), and 12 cohort studies (12, 16-18, 20, 21, 23- 25, 29, 35, 36). The primary locations included USA, 
UK, Finland, Denmark, French, Ita y, and Canada. No participants with a prior diagnosis of 
Alzheimer's disease, dementia, or P rkinson's disease at baseline were included in the cohort studies 
or RCTs included. The studies ex mined applied hormone therapies which were composed of 
estrogen, progesterone (or its derivatives), or a combined formulation of the two hormones. The 
majority of included studies we e found to be of high quality according to Supplemental Table 2, with 
11 returning a score of nine (12, 16, 17, 20-22, 24, 27, 33, 35, 38). 
 
3.3. Associati n f HT use with neurodegenerative disease 
 
Fourteen studies containing 19 arms reported on the relationship between HT and Alzheimer's disease as 
outcome measure (11, 12, 20, 24, 26, 29-32, 34-38). The pooled OR (95% CI) in the hormone-treated versus 
hormone-naïve was OR 1.08 for Alzheimer's disease (95% CI 1.03 -1.14, I2: 69%) (Fig. 2). Furthermore, five 
studies with nine arms reported dementia OR as their outcome measure (14, 19, 21, 24, 25) and the 
combined analysis identified a significant direct relationship between HT use and 
 
 
dementia (OR 1.16, 95% CI 1.02 -1.31, I2: 19%). Finally, in ten studies with 22 arms (15-19, 22, 23, 27, 
28, 33) the association between Parkinson's disease in HT was not found to be significant (OR 1.14, 
95% CI 0.95-1.38, I2: 65%). 
 
3.4. Association of HT formulation with neurodegenerative disease 
 
We subsequently stratified studies for Alzheimer's disease and Parkinson's disease based on the 
formulation of used hormone (Figure 3) and the design of the primary studies (Supplementary Fig. 1). 
These analyses showed that different hormone have varying effects on disease occurrence (heterogeneity 
between group was p=0.005 for Alzheimer's disease results and p=0.002 for Parkinson's disease). Indeed, 
the relationship between HT and Alzheimer's disease was f und to be stronger in patients using the 
combined estrogen-progestogen formulati n (OR 1.16, 95% CI 1.12 - 1.21), while progestogen only (OR 1.13, 
95% CI 1.10 - 1.17) and est ogen nly therapies remained associated with the disease, but displayed a slighty 
less concerning effect level (OR 1.09, 95% CI 1.06 - 1.11). The relationship between HT and Parkinson's 
disease was found to be strongest in patients using the progestogen only therapy (OR 3.41, 95% CI 1.23 
9.46), while the combined estrogen-progestogen formulation also displayed disease association, but again 
with a more modest effect size (OR 1.49, 95% CI 1.34 -1.65). Interestingly, our meta-analysis sugg sts that 
estrogen-only formulations have no significant associations with Parkinson's disease development (OR 
1.08, 95% CI 0.90 - 1.22). 
 
3.5. Effect of study design on HT-neurodegenerative disease interaction 
 
Interestingly, while a significant rel tionship was identified between HT and Alzheimer's disease in the 
included case-control studies (OR 1.12, 95% CI 1.10 - 1.13), no such effect was detected in the included 
cohort studies (OR 0.89, 95% CI 0.76 - 1.04). Conversely, the relationship between HT and Parkinson's 
disease was significant in cohort studies (OR 1.39, 95% CI 1.28 - 1.52) and not the included case-control st 
dies (OR 0.96, 95% CI 0.74 - 1.26). Moreover, the relationship between HT and dementia was significant in 
the included RCTs (OR 1.16, 95% CI 1.02 - 1.32), but the same effect was not achieved in the included cohort 
studies (OR 1.13, 95% CI 0.97 - 1.33). Finally, meta-regression based on baseline age of participants did not 
reveal this variable as a source of heterogeneity for Alzheimer’s disease, Parkinson's disease, or dementia 
diagnosis (Supplemental Fig 2). 
 
3.6. Time-response analysis  
 
A significant association between duration of HT and Alzheimer's disease, which is direct in initial 
five years and inverse in subsequent years (Coef1 =0.0477, p1<0.001; Coef2 = -0.0932, p2<0.001), was 
noted in the present meta-analysis (Fig 4). The combined OR was significant and direct between 
duration of HT and Parkinson's disease in first 5 years of HT (Coef1 =0.0626, p1=0.04), but non-
significant in years afterwards (Coef2 = -0.0427, p2=0.21). 
 
3.7. Publication bias 
 
Supplementary Figure 3 includes funnel plots which indicate that there was publication bias among 
the studies reporting on Alzheimer's disease (Begg’s p=0.17 and Egger regression test p=0.02), but not 
for dementia (Begg’s p=0.67 and Egger regression test p=0.77) or Parkinson's disease (Begg’s p=0.59 
and Egger regression test p=0.05). The ‘trim and fill’ method was applied in rder to adjust for 
publication bias identified in Alzheimer's disease reporting studies (Supplemental Table 3). Finally, 
the sensitivity analysis does not show significant differences beyond the limits of 95% CI of calculated 




HT represents a stalwart of symptomatic management in menopausal women and while such 
therapies have demonstrated unparalleled efficacy in this application, their association with 
neurodegenerative disease remains equivocal. As a result, we sought to determine the relationship 
between menopausal HT and Alzheimer's disease, all-cause dementia, and Parkinson's disease in 
human subjects. The present meta- n lysis, which included data from case-control, controlled trial and 
cohort design studies, fou d th t ny HT-use was significantly associated with development of 
Alzheimer’s disease and deme tia of undefined etiology, whilst no such effect was uncovered for 
Parkinson’s disease. In addition, sub-group analysis revealed that combined estrogen-progestogen 
formulations prod ced higher odds of Alzheimer’s disease when compared to therapies containing 
progestogen, estr gen or estradiol alone. With respect to Parkinson’s disease, progestogen only and 
combined estr gen-progestogen formulations were significantly associated the disease while other 
therapies were not. Finally, we reveal a significant direct association between duration of HT with 
Alzheimer’s and Parkinson’s disease in the first five years of treatment. 
 
A number of observational investigations have previously reported a significant Alzheimer’s disease 
and dementia risk reduction in those prescribed HT (20, 39-42). However, questions remain around 
the veracity and generalizability of these findings, as the original studies generally lack sufficient 
 
 
control and selection bias towards healthy females may have existed in HT groups. Indeed, this 
suspicion was supported by the results of the placebo-controlled WHIMS trial, in which the authors 
observed an increased risk of impaired cognition and dementia in women using certain forms of HT 
(43, 44). However, the design of the WHIMS trial itself has not been free of criticism, since HT was 
commenced more than a decade on from the typical age of menopausal onset, a practice which is not 
the standard. In addition, the WHIMS cohort were not differentiated according to etiology of cognitive 
decline and it is conceivably that each process may respond differently to HT exposure (43, 44). 
Importantly, a recently updated Cochrane review by Marjoribanks et al. concluded that HT is not 
suitable for the prevention of dementia or cognitive decline in postmenopausal women (45). This lack 
of protection is an important message to disseminate considering the results f the present meta-
analysis, which indicates that HT may in fact be a contributory factor in the devel pment of such 
neurodegenerative diseases. 
 
Although a number of histological characteristics have been identified as osthumous hallmarks of the 
pathology, the precise underlying cause of Alzheimer’s disease is not entirely understood (46, 47). As 
a result, it remains a challenge to pinpoint the mechanisms through which HT may interact with the 
disease, be it in a beneficial or harmful manner. How v r, it has been reported that the risk of 
Alzheimer’s disease may increase in a graded fashion with each full-term pregnancies, an effect which 
is postulated to be the result of repeated exposure to estrogen-progesterone surges (48). Conversely, 
several mechanisms exist through which HT may be considered to protect against the disease, 
including improvements in cerebral b ood f ow (49, 50), increases in dendritic spine density (51-53), 
and nerve growth factor inter ctions (54). A narrative which arose from cardiovascular outcome 
observations around HT suggest th t there may be an important temporal nature to the interaction. 
Specifically, it is suggested that estrogen may only be neuroprotective if initiated soon after 
menopausal onset, a theo y which largely arose following the WHIMS trials revelations. This 
speculative hypothesis, otherwise termed the ‘critical window’ theory, has support in animal-based 
models (55). The evidence from animal models suggests that HT during the ‘critical window’ is linked 
to neuropr tecti n through reduced deposition of β-amyloid, synaptic formation improvements, 
increased choline acetyltransferase activity, and improvements in cerebral perfusion (56-58). This 
‘critical window’ hypothesis may explain why HT beyond the initial five years was inversely 
associated with incidence in the context of Alzheimer’s disease. 
 
Investigations into the use of HT and risk for Parkinson's disease have yielded inconsistent findings, which 
suggests that the interaction between HT and Parkinson's disease is complex and multi-faceted 
 
 
(27, 59-63). Indeed, in the present study, we found no significant association between HT and 
Parkinson’s disease. Despite this, sub-group analysis of specific HT types revealed a significantly 
higher risk of Parkinson's disease development in those treated with progestogen and combined 
estrogen-progestogen formulations. Although this putative relationship indeed warrants further 
elucidation, it is important to note that just a single study examined the effect of progesterone-only 
HT on Parkinson’s disease. Therefore, this result should be replicated, preferably in an RCT setting, 
before this phenomenon is to be treated as reliable. 
 
In the present mixed-source meta-analysis, we further examined the effect of data origin on the 
association of HT with neurodegenerative disease through stratification by study design. According 
to the hierarchy of evidence, RCT-derived data represents the most reliable form f inf rmati n, while 
case-control and cohort design studies are inferior but relatively equal in their veracity. In the context 
of Alzheimer’s disease, we found that the association with HT was maintained f llowing meta-analysis 
of case control studies in isolation; however, no such effect was obse ved when cohort studies were 
examined independently. Contrastingly, when Parkinson’s studies were stratified, we found that 
cohort-derived data showed a significant effect, while case control studies did not. Finally, in the case 
of dementia, meta-analysis of RCT data maintain d the same effect size and direction, while cohort 
study-specific meta-analysis revealed no significant association. These results indicate that, while 
there was a degree of discord amongst study designs, there was no consistent and substantial impact 
of design on the overall study outcome. In addition, we can be reassured by the fact that no sub-group 
meta-analysis revealed a significant opposing effect and the RCT-specific meta-analysis of all-cause 
dementia is in keeping with the overall result. 
 
Strengths and limitations 
 
There are a number of significant strengths of the present work which are important to note. Firstly, the 
present study has provided better clarity into the effect of HT on Alzheimer’s disease, all-cause dementia 
and Parkinson’s disease, by integrating results from 14 case-control (11, 13, 15, 22, 26-28, 30-34, 37, 38), two 
were RCTs (14, 19), and 12 cohort studies (12, 16-18, 20, 21, 23-25, 29, 35, 36). Furthermore, the sensitivity 
analysis showed no significant differences beyond the limits of 95% CI of calculated combined results for 
each of included studies, suggesting that their inclusion was justified and the findings are reliable. Despite 
the aforementioned strengths, this meta-analysis also possesses several limitations. Although the total 
included population of pooled participants in the present meta-analysis is considerable, the sample size of 
several individual studies was relatively small. It is 
 
 
conceivable that a small sample size may influence the detection of rare outcomes, particularly in 
relation to less common neurodegenerative diseases (64). Furthermore, the dose and timing may 
represent impactful factors in determining the neuroprotective or neurodegenerative effects of such 
treatments and, although we explored the temporal effects, we have not explored any potential dose-
response associations. We must also recognise the substantial weight which was attributed to a small 
number of studies in the Alzheimer's disease meta-analysis. Although weight to each study was 
related to sample size and precision of that study, as is the gold standard practice of meta-analysis, 
this has resulted in a disproportionate representation of a select number of studies. Furthermore, we 
did not have any RCT-derived data to draw from for the Alzheimer's disease and Parkinson's disease 
meta-analysis. It is recommended that double-blind RCTs be conducted in rder to c nfirm the veracity 




This study revealed a significant and direct relationship between HT and Alzheimer's disease or all-
cause dementia in postmenopausal women. However, this effect is limited to the first five years of 
therapy in Alzheimer’s disease and in fact the direction of association appears to reverse in the years 
to follow. In addition, certain formulations of HT we e found to be associated with an elevated risk of 
Parkinson’s disease. Although this study integrated data from both observational and controlled trial 
study designs, the results remain consistent and indicate that large-scale RCT investigations into the 
long-term safety of different HTs in the context of neurodegenerative disease and cognitive demise 
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Savolainen-Peltonen, H. (2019)  1.06 (1.01, 1.12) 14.45 
Savolainen-Peltonen, H. (2019)  1.14 (1.09, 1.19) 15.10 
Savolainen-Peltonen, H. (2019)  1.15 (1.06, 1.25) 11.66 
Savolainen-Peltonen, H. (2019)  1.23 (1.14, 1.32) 12.49 
Imtiaz, B. (2017)  0.92 (0.69, 1.22) 2.62 
Imtiaz, B. (2017)  1.10 (0.84, 1.44) 2.81 
Imtiaz, B. (b) (2017)  1.10 (1.07, 1.13) 16.26 
Imtiaz, B. (b) (2017)  1.13 (1.10, 1.17) 16.05 
Shao, Huibo (2012)  0.80 (0.58, 1.10) 2.18 
Ryan, J. (2009)  1.36 (0.44, 4.20) 0.19 
Roberts, R. O. (2006)  1.10 (0.63, 1.93) 0.76 
Lindsay, Joan (2002)  1.37 (0.48, 3.93) 0.22 
Seshadri, S. (2001)  1.18 (0.59, 2.36) 0.50 
Waring, S. C. (1999)  0.42 (0.18, 0.97) 0.35 
Baldereschi, M. (1998)  0.24 (0.07, 0.80) 0.17 
Kawas, C. (1997)  0.46 (0.21, 1.02) 0.38 
Tang, M. X. (1996)  0.40 (0.20, 0.79) 0.53 
Paganini-Hill, A. (1996)  0.65 (0.49, 0.87) 2.48 
Brenner, D. E. (1994)  1.10 (0.64, 1.91) 0.79 
Overall  (I-squared = 69.0%, p = 0.000)  1.08 (1.03, 1.14) 100.00 
NOTE: Weights are from random effects analysis    











Study   % 
ID  OR (95% CI) Weight 
Espeland, M. A. (2015)  0.99 (0.77, 1.28) 16.44 
Espeland, M. A. (2015)  1.15 (0.98, 1.35) 29.03 
Manson, J. E. (2013)  2.01 (1.19, 3.41) 4.86 
Manson, J. E. (2013)  1.47 (0.85, 2.53) 4.61 
Whitmer, R. A(2011).  1.02 (0.78, 1.34) 15.00 
Ryan, J. (2009)  0.74 (0.35, 1.56) 2.55 
Ryan, J. (2009)  0.83 (0.32, 2.16) 1.57 
Petitti, D. B. (2008)  1.23 (0.95, 1.60) 15.66 
Petitti, D. B. (2008)  1.34 (0.95, 1.89) 10.29 
Overall (I-squared = 19.8%, p = 0.267)  1.16 (1.02, 1.31) 100.00 
NOTE: Weights are from random effects analysis    






c) Parkinson's disease  
 
 
Study    % 
ID  OR (95% CI) Weight 
Lundin, J. I. (2014)  1.70 (0.59, 4.91) 2.32 
Lundin, J. I. (2014)  0.50 (0.20, 1.22) 2.96 
Lundin, J. I. (2014)  6.90 (2.09, 22.79) 1.93 
Lundin, J. I. (2014)  3.00 (0.52, 17.44) 1.00 
Liu, R. (2014)  1.27 (0.90, 1.79) 7.21 
Liu, R. (2014)  1.47 (1.09, 1.98) 7.65 
Liu, R. (2014)  1.71 (1.01, 2.89) 5.41 
Gatto, N. M. (2014)  0.72 (0.42, 1.23) 5.30 
Gatto, N. M. (2014)  0.95 (0.62, 1.45) 6.36 
Gatto, N. M. (2014)  1.57 (1.40, 1.77) 9.18 
Rugbjerg, K. (2013)  0.60 (0.22, 1.65) 2.49 
Rugbjerg, K. (2013)  1.45 (0.85, 2.48) 5.32 
Nicoletti, A. (2011)  0.99 (0.27, 3.60) 1.70 
Simon, K. C(2009).  1.28 (0.93, 1.77) 7.38 
Simon, K. C(2009).  3.41 (1.23, 9.46) 2.46 
Simon, K. C(2009).  0.97 (0.65, 1.44) 6.63 
Simon, K. C(2009).  1.04 (0.71, 1.53) 6.74 
Popat, RA (2005)  1.30 (0.80, 2.11) 5.80 
Currie, L. J. (2005)  0.40 (0.19, 0.84) 3.78 
Benedetti, M. D. (2001)  0.47 (0.12, 1.85) 1.55 
Marder, Karen (1998)  0.24 (0.07, 0.80) 1.90 
Marder, Karen (1998)  1.02 (0.57, 1.83) 4.91 
Overall (I-squared = 65.1%, p = 0.000)  1.14 (0.95, 1.38) 100.00 
NOTE: Weights are from random effects analysis     






Figure 3. The forest plot of s bgro  p analysis of Hormone therapy based on type of used hormone and odd ratio of: 
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